Ulven T - Search Results

1

Structure-Activity Study of Dihydrocinnamic Acids and Discovery of the Potent FFA1 (GPR40) Agonist TUG-469.

Christiansen E, Due-Hansen ME, Urban C, Merten N, Pfleiderer M, Karlsen KK, Rasmussen SS, Steensgaard M, Hamacher A, Schmidt J, Drewke C, Petersen RK, Kristiansen K, Ullrich S, Kostenis E, Kassack MU, Ulven T. Christiansen E, et al. Among authors: ulven t. ACS Med Chem Lett. 2010 Jul 2;1(7):345-9. doi: 10.1021/ml100106c. eCollection 2010 Oct 14. ACS Med Chem Lett. 2010. PMID: 24900217 Free PMC article.

2

Minor structural modifications convert the dual TP/CRTH2 antagonist ramatroban into a highly selective and potent CRTH2 antagonist.

Ulven T, Kostenis E. Ulven T, et al. J Med Chem. 2005 Feb 24;48(4):897-900. doi: 10.1021/jm049036i. J Med Chem. 2005. PMID: 15715457

3

Identification of indole derivatives exclusively interfering with a G protein-independent signaling pathway of the prostaglandin D2 receptor CRTH2.

Mathiesen JM, Ulven T, Martini L, Gerlach LO, Heinemann A, Kostenis E. Mathiesen JM, et al. Among authors: ulven t. Mol Pharmacol. 2005 Aug;68(2):393-402. doi: 10.1124/mol.104.010520. Epub 2005 May 3. Mol Pharmacol. 2005. PMID: 15870392

4

A physicogenetic method to assign ligand-binding relationships between 7TM receptors.

Frimurer TM, Ulven T, Elling CE, Gerlach LO, Kostenis E, Högberg T. Frimurer TM, et al. Among authors: ulven t. Bioorg Med Chem Lett. 2005 Aug 15;15(16):3707-12. doi: 10.1016/j.bmcl.2005.05.102. Bioorg Med Chem Lett. 2005. PMID: 15993056

5

Emerging roles of DP and CRTH2 in allergic inflammation.

Kostenis E, Ulven T. Kostenis E, et al. Among authors: ulven t. Trends Mol Med. 2006 Apr;12(4):148-58. doi: 10.1016/j.molmed.2006.02.005. Epub 2006 Mar 20. Trends Mol Med. 2006. PMID: 16545607 Review.

6

Targeting the prostaglandin D2 receptors DP and CRTH2 for treatment of inflammation.

Ulven T, Kostenis E. Ulven T, et al. Curr Top Med Chem. 2006;6(13):1427-44. doi: 10.2174/15680266106061427. Curr Top Med Chem. 2006. PMID: 16918458 Review.

7

Novel selective orally active CRTH2 antagonists for allergic inflammation developed from in silico derived hits.

Ulven T, Receveur JM, Grimstrup M, Rist Ø, Frimurer TM, Gerlach LO, Mathiesen JM, Kostenis E, Uller L, Högberg T. Ulven T, et al. J Med Chem. 2006 Nov 16;49(23):6638-41. doi: 10.1021/jm060657g. J Med Chem. 2006. PMID: 17154491

8

Synthesis and in vitro evaluation of a selective antagonist and the corresponding radioligand for the prostaglandin D2 receptor CRTH2.

Ulven T, Gallen MJ, Nielsen MC, Merten N, Schmidt C, Mohr K, Tränkle C, Kostenis E. Ulven T, et al. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5924-7. doi: 10.1016/j.bmcl.2007.07.080. Epub 2007 Aug 22. Bioorg Med Chem Lett. 2007. PMID: 17845848

9

Discovery of potent and selective agonists for the free fatty acid receptor 1 (FFA(1)/GPR40), a potential target for the treatment of type II diabetes.

Christiansen E, Urban C, Merten N, Liebscher K, Karlsen KK, Hamacher A, Spinrath A, Bond AD, Drewke C, Ullrich S, Kassack MU, Kostenis E, Ulven T. Christiansen E, et al. Among authors: ulven t. J Med Chem. 2008 Nov 27;51(22):7061-4. doi: 10.1021/jm8010178. J Med Chem. 2008. PMID: 18947221

10

The C-terminal tail of CRTH2 is a key molecular determinant that constrains Galphai and downstream signaling cascade activation.

Schröder R, Merten N, Mathiesen JM, Martini L, Kruljac-Letunic A, Krop F, Blaukat A, Fang Y, Tran E, Ulven T, Drewke C, Whistler J, Pardo L, Gomeza J, Kostenis E. Schröder R, et al. Among authors: ulven t. J Biol Chem. 2009 Jan 9;284(2):1324-36. doi: 10.1074/jbc.M806867200. Epub 2008 Nov 14. J Biol Chem. 2009. PMID: 19010788 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

122 results

Search Page

Filters